Pharma BD Deal Intelligence
Dimerix snaps up Mission's Phase 2-ready kidney disease candidate MTX652 for $5M upfront in a deal worth up to $292M.
Mission Therapeutics divests MTX652 to Dimerix in a deal worth up to $292 million; milestone breakdown detailed.
Source summaries from our enrichment pipeline; follow links for originals.
All 3 sources with sentiment breakdown →
Dimerix Limited licensed MTX652, a Phase 2-ready selective USP30 inhibitor for acute kidney injury, from Mission Therapeutics in a deal announced July 17, 2026 worth up to $292 million. Dimerix pays $5 million upfront plus up to $287 million in clinical, regulatory and sales milestones and up to double-digit tiered royalties on global net sales. The divestiture lets Mission sharpen its focus on its CNS pipeline while Dimerix, an ASX-listed renal specialist, adds a mechanistically differentiated mitochondrial-protection asset to its kidney-disease portfolio.
← Browse all deals · How we score deals
More: 2026 deals